TransPharma Medical Receives Second Milestone Payment from Teva Pharmaceutical Industries
13-Jun-2007
- Israel
The milestone achieved is in line with the product development plan of hGH, the first of up to five molecules designated for joint development by TransPharma and Teva in an agreement originally signed between the two companies in 2004. Under the agreement, Teva will exclusively market each of the drug products and will pay TransPharma milestone payments, royalties, and development costs.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.